Welcome to our dedicated page for Accelerate Diagnostics SEC filings (Ticker: AXDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accelerate Diagnostics, Inc. SEC filings document an in vitro diagnostics issuer with common stock that moved from Nasdaq trading to OTC Pink quotation under the AXDXQ symbol after Nasdaq suspension. The filings cover the company’s Delaware corporate status, registered common stock, material definitive agreements and public-company reporting obligations.
Recent regulatory records include 8-K disclosures tied to Chapter 11 proceedings involving Accelerate Diagnostics and its U.S. subsidiary, Accelerate Diagnostics Texas, LLC. Form 25 records the removal of the company’s common stock from Nasdaq listing and Section 12(b) registration, while Form 12b-25 notices document delayed quarterly-report filing matters.
Accelerate Diagnostics, Inc. has notified regulators that it cannot file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 without unreasonable effort or expense. The company is operating under Chapter 11 bankruptcy in Delaware and has been pursuing an asset sale.
The court has approved a liquidation plan and an amended asset purchase agreement under which a buyer will acquire certain assets and liabilities. On the plan’s effective date, all outstanding common stock, related equity awards, and warrants will be canceled, and holders will not receive any property. The company notes its June 2025 results likely differ significantly from a year earlier due to these adverse developments and cannot estimate when or if it will file the 10-Q.
Accelerate Diagnostics, Inc. and its U.S. subsidiary filed voluntary Chapter 11 petitions and have entered an amended and restated Asset Purchase Agreement with an affiliate of Indaba Capital Management for the planned sale of company assets. The A&R Purchase Agreement narrows the buyer's acquisition to certain assets and liabilities rather than "substantially all" assets. The Bankruptcy Court entered a Confirmation Order approving the Second Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation, and the Company Parties intend to effect the transactions contemplated by the Plan after satisfaction or waiver of the Plan's conditions.
Nasdaq Stock Market LLC has filed Form 25 to remove Accelerate Diagnostics, Inc. (AXDX) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The notice, signed on 2025-07-21 by Hearings Advisor Aravind Menon, states that Nasdaq believes it meets all requirements for the filing. The company’s securities will cease to be listed once the Form 25 becomes effective and the Exchange Act registration will be withdrawn unless the SEC objects. No financial or earnings data accompany this low-complexity filing; the sole purpose is the formal delisting of AXDX shares.
Gilbert E. Nathan has filed a Form 3 (Initial Statement of Beneficial Ownership) following his appointment as Director at Accelerate Diagnostics (AXDX). The filing, dated June 28, 2025, discloses Nathan's beneficial ownership position as of April 10, 2025.
Key details from the filing:
- Nathan currently holds no securities (derivative or non-derivative) beneficially owned in the company
- The filing confirms his position as Director but indicates no other roles such as Officer or 10% Owner
- This is an individual filing, not a joint/group submission
- Business address is listed as 3950 S. Country Club Road, Suite 470, Tucson, AZ 85714
This Form 3 filing is a standard regulatory requirement for new directors under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future ownership reporting.